Brief: Core Biomedicine Signs Exclusive Licensing Agreement With Eisai For Precision Oncology Programs
28/07/2026 13:24
BRIEF-Core Biomedicine Signs Exclusive Licensing Agreement With Eisai For Precision Oncology Programs July 28 (Reuters) - Eisai Co Ltd 4523.T:
CORE BIOMEDICINE SIGNS EXCLUSIVE LICENSING AGREEMENT WITH EISAI FOR PRECISION ONCOLOGY PROGRAMS
CORE BIOMEDICINE: CO OBTAINED EXCLUSIVE, GLOBAL RIGHTS TO CERTAIN PRECLINICAL ONCOLOGY PROGRAMS THAT TARGET KEY MOLECULAR DRIVERS OF VARIOUS CANCERS
Source text: ID:nPn11SNn4a
Further company coverage: 4523.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eisai
See all newsBiogen tops quarterly estimates on rare-disease drug strength (updated)
Biogen beats third-quarter results on strength in rare disease drugs
Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Leqembi Pen (Subcutaneous Formulation Of Leqembi) Approved In Japan
Leqembi (Lecanemab) Subcutaneous Formulation As An Initiation Treatment For Early Alzheimer's Disease Approved In China